Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane®
(nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and
tolerability. When combined with a taxane, platinum agents improve response in metastatic
breast cancer, with carboplatin conferring less toxicity than cisplatin. Monoclonal
antibodies including bevacizumab target vascular endothelial growth factor (VEGF) to reduce
angiogenesis. We hypothesize that the previously-untested combination of weekly Abraxane® and
carboplatin plus biweekly bevacizumab will lengthen time to progression without producing
intolerable toxicity.